SC
COLL icon

Stephens Consulting’s Collegium Pharmaceutical COLL Stock Holding History

Stephens Consulting’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1
Closed -$30 – 562
2025
Q2 		$30 Sell
1
-14
-93% -$399 ﹤0.01% 1150
2025
Q1 		$448 Buy
+15
New +$458 ﹤0.01% 948

Other funds holding COLL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Stephens Consulting's COLL Position: Q3 2025 in Review

Stephens Consulting sold out of Collegium Pharmaceutical (COLL) in Q3 2025, closing a stake of 1 share — an estimated $30 sold.

Stephens Consulting first reported a position in COLL in Q1 2025 and held it in 2 quarters. The position peaked at $448 in Q1 2025. 244 funds tracked by Wall St. Rank hold COLL as of Q3 2025.

  • Stephens Consulting reported no remaining Collegium Pharmaceutical position as of Q3 2025 after selling out during the quarter.
  • Stephens Consulting sold 1 Collegium Pharmaceutical share in Q3 2025, an estimated $30.
  • Stephens Consulting first reported a position in Collegium Pharmaceutical in Q1 2025 and held it in 2 quarters.
  • Stephens Consulting's Collegium Pharmaceutical position peaked at $448 in Q1 2025.
  • 244 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q3 2025.

Based on Stephens Consulting's 13F filing for Q3 2025, filed 15 Oct 2025.